

Edgar Filing: VITAL LIVING INC - Form SC 13D

VITAL LIVING INC
Form SC 13D
August 29, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D
UNDER THE EXCHANGE ACT OF 1934

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULE 13d-1(a)

VITAL LIVING, INC.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

92846Y100

(CUSIP Number)

DONALD NICHOLSON
SKYEPHARMA PLC
105 PICCADILLY
LONDON W1J 7NJ, ENGLAND
+44 20 7491 1777

KATHRYN A. CAMPBELL, ESQ.
SULLIVAN & CROMWELL LLP
1 NEW FETTER LANE
LONDON EC4A 1AN, ENGLAND
+44 20 7959 8900

(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)

AUGUST 20, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

(continued on following pages)

CUSIP NO. 92846Y100

PAGE 2 OF 9 PAGES

1 Names Of Reporting Persons
I.R.S. Identification Nos. of Above Persons

Edgar Filing: VITAL LIVING INC - Form SC 13D

SKYEPHARMA PLC
330387911

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS

WC, OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

ENGLAND AND WALES

7 SOLE VOTING POWER

0

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON WITH

8 SHARED VOTING POWER

36,018,973(1)(2)

9 SOLE DISPOSITIVE POWER

15,204,548(2)

10 SHARED DISPOSITIVE POWER

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

15,204,548(1)(2)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

27.66%(2)(3)

14 TYPE OF REPORTING PERSON

CO

1 In order to facilitate the consummation of the transaction contemplated
by the Agreement and Plan of Merger by and among Vital Living, Inc.
(the "Issuer"), VLEN Acquisition

CUSIP NO. 92846Y100

PAGE 3 OF 9 PAGES

Corp., Inc. ("VLEN") and E-Nutriceuticals, Inc. ("ENI"), dated as of August 20, 2003 (the "Merger Agreement", and the transaction contemplated thereby, the "Merger"), SkyePharma PLC ("SkyePharma") entered into a Stockholders' Agreement with the Issuer and the other parties listed therein, dated as of August 20, 2003 (the "Stockholders' Agreement"), whereby each of Bradley Edson ("Mr. Edson"), Stuart Benson ("Mr. Benson") and Donald Hannah (Mr. Hannah, and with Mr. Edson and Mr. Benson, the "Founders Group"), Fifth Avenue Capital, Inc. ("Fifth Avenue Capital") and Stephen Morris ("Mr. Morris, and with Fifth Avenue Capital, the "Morris Group"), and SkyePharma (collectively, the "Stockholders") agreed to vote its shares of common stock, par value \$0.001 per share (the "Common Stock") of Vital Living, options, warrants or convertible securities to purchase Common Stock, and other voting securities (the "Shares") of the Issuer to elect the directors nominated by the other Stockholders. SkyePharma does not have the right to dispose or direct the disposition of any of the 20,814,425 shares of Common Stock or securities convertible or exercisable into Common Stock owned by the other parties to the Stockholders' Agreement. Accordingly, SkyePharma expressly disclaims beneficial ownership of all such shares.

2 SkyePharma is currently the beneficial owner of 14,204,548 shares of Common Stock and 1,000,000 shares of Series D Convertible Preferred Stock, par value \$0.001 per share, of the Issuer (the "Preferred Stock"). Accordingly, SkyePharma has beneficial ownership of 15,204,548 shares of Common Stock, assuming the conversion of all shares of Preferred Stock owned or to be purchased by SkyePharma into Common Stock at the current conversion price of \$1.00.

3 Based on 54,965,726 shares of Common Stock outstanding on consummation of the Merger on August 20, 2003, as described in Section 3.4(c) of the Subscription Agreement between SkyePharma and the Issuer, dated as of August 20, 2003 (the "Subscription Agreement") and the conversion of 1,000,000 shares of Preferred Stock into 1,000,000 shares of Common Stock.

ITEM 1 SECURITY AND ISSUER

This statement on Schedule 13D (the "Statement") relates to the Common Stock of Vital Living, Inc., a Nevada corporation, including such Common Stock issuable upon conversion of Preferred Stock held by SkyePharma. The Issuer's principal executive offices are located at 5080 North 40th Street, Suite #105, Phoenix, Arizona, 85018.

ITEM 2 IDENTITY AND BACKGROUND

SkyePharma is a company incorporated under the laws of England and Wales. The principal business of SkyePharma is the use of its multiple drug delivery technologies, specifically oral, injectable, inhalation, topical and enhanced solubility, to create a product pipeline for out-licensing to marketing partners. The business address of SkyePharma is SkyePharma PLC, 105 Piccadilly, London, England W1J 7NJ.

Neither SkyePharma, nor, to its knowledge and belief, any of its executive officers or directors, has during the last five years been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

CUSIP NO. 92846Y100

PAGE 4 OF 9 PAGES

Annex A hereto sets forth with respect to each executive officer and director of SkyePharma the following information: (i) name, (ii) residence or business address, (iii) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted and (iv) citizenship.

ITEM 3 SOURCES AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The source of funds for the 1,000,000 shares of Preferred Stock to which this Statement relates was SkyePharma's working capital. The total amount was \$1,000,000 in cash, which was paid on August 21, 2003, in accordance with the Subscription Agreement.

The consideration for the 14,204,548 shares of Common Stock was SkyePharma's shares of ENI common stock, as determined pursuant to the Merger Agreement.

To SkyePharma's knowledge and belief, none of its executive officers or directors named in Annex A hereto, beneficially owns any shares of Common Stock.

ITEM 4 PURPOSE OF THE TRANSACTION

The purpose of the acquisition of the Common Stock and the Preferred Stock by SkyePharma was and is for investment. The Preferred Stock was acquired pursuant to the Subscription Agreement simultaneous with and as a condition to consummation of the Merger of ENI and VLEN, a wholly-owned subsidiary of the Issuer. The Common Stock was acquired by SkyePharma pursuant to the Merger Agreement in exchange for its interest in ENI, which interest was also held for investment purposes. SkyePharma's ENI common stock, were converted and exchanged for shares of Common Stock of the Issuer on August 20, 2003. As a result of the Merger, VLEN's separate corporate existence ceased and ENI became the wholly-owned subsidiary of the Issuer, in which SkyePharma has a 27.66% interest, including the 1,000,000 shares of Common Stock issuable on conversion of the Preferred Stock based on a current conversion price of \$1.00.

Pursuant to the terms of the Commitment Letter between SkyePharma and the Issuer, dated as of August 20, 2003, executed pursuant to Section 5 of the Merger Agreement, SkyePharma has committed to invest 1,000,000 U.S. dollars in the event that the Issuer raises an additional 3,000,000 U.S. dollars in an equity offering completed within 90 days of the Closing of the Merger, as defined in the Merger Agreement, subject to the terms of such Commitment Letter. This obligation, if consummated, would be expected to result in an additional holding of 1,000,000 preferred convertible securities (the "Additional Preferred Stock") convertible into approximately 1,000,000 shares of Common Stock or more, depending on the price of such issuance and the conversion price and other terms of the Additional Preferred Stock.

SkyePharma is continuously evaluating the business and business prospects of the Issuer, and its present and future interests in, and intentions with respect to the Issuer and at any time may decide to acquire additional shares or dispose of any or all of the shares of Common Stock or Preferred Stock owned by it.

SkyePharma currently intends to exercise its rights as shareholder in

Edgar Filing: VITAL LIVING INC - Form SC 13D

the Issuer, and in connection therewith, may, from time to time, (i) have discussion with management and/or other shareholders of the Issuer concerning various operational and financial aspects of the Issuer's business, (ii) make one or more proposals to the Issuer or other shareholders of the Issuer relating to joint ventures, mergers, business combinations or extraordinary transactions, and (iii) solicit proxies.

CUSIP NO. 92846Y100

PAGE 5 OF 9 PAGES

Pursuant to the terms of the Stockholders' Agreement, SkyePharma will vote its Common Stock and Preferred Stock which vote with the Common Stock together with certain other shareholders of the Issuer after the Merger, as described in more detail in Item 6 of this Statement.

Except as set forth in this Statement, as of the date of the filing of this Statement, neither SkyePharma, nor, to its knowledge and belief, any of its executive officers or directors, has any other plan or proposal which relates to or would result in any of the actions specified in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

ITEM 5 INTEREST IN SECURITIES OF THE ISSUER

(a) The percentage interest held by SkyePharma presented below is based on 54,965,726 shares of Common Stock outstanding on consummation of the Merger on August 20, 2003, as represented by the Issuer in Section 3.4(c) of the Subscription Agreement. Assuming the conversion of all shares of Preferred Stock owned by SkyePharma into Common Stock at a conversion price of \$1.00, SkyePharma is the beneficial owner of 15,204,548 shares of Common Stock, including Common Stock issuable on the conversion of convertible securities of the Issuer, representing approximately 27.66% of the Common Stock issued and outstanding. The information in this Statement with respect to the parties listed below in this Item 5(a) is based solely on information provided by the Issuer to SkyePharma. Mr. Edson is the beneficial owner of 5,046,950 shares of Common Stock, including Common Stock issuable on the conversion of convertible securities and the exercise of options and warrants, representing approximately 9.18% of the Common Stock issued and outstanding. Mr. Benson is the beneficial owner of 6,340,000 shares of Common Stock, including Common Stock issuable on the conversion of convertible securities and the exercise of options and warrants, representing approximately 11.53% of the Common Stock issued and outstanding. Mr. Hannah is the beneficial owner of 536,900 shares of Common Stock, representing approximately 0.98% of the Common Stock issued and outstanding. Fifth Avenue Capital is the beneficial owner of 8,860,575 shares of Common Stock, representing approximately 16.12% of the Common Stock issued and outstanding. Stephen Morris is a principal of Fifth Avenue Capital. Mr. Morris is individually the beneficial owner of 30,000 shares of Common Stock issuable on the conversion of convertible securities and the exercise of options and warrants, representing approximately 0.05% of the Common Stock issued and outstanding. Except as set forth in this Item 5, neither SkyePharma, nor to its knowledge and belief, any of its executive officers or directors named in Annex A hereto, beneficially owns any shares of Common Stock.

(b) SkyePharma has the shared power to vote or to direct the vote of, and the sole power to dispose or direct the disposition of, its 1,000,000

Edgar Filing: VITAL LIVING INC - Form SC 13D

shares of Common Stock that would be issued on the conversion of all of its shares of Preferred Stock based on the current conversion price and its 14,204,548 shares of Common Stock. Each of the Persons listed in Item 5(a) has the shared power to vote or direct the vote and the sole power to dispose or direct the disposition of the shares of Common Stock attributed to them in that Item.

Mr. Edson, a citizen of the United States of America, is the Chief Executive Officer and Chairman of the Board of Vital Living. Mr. Benson, a citizen of the United States of America, is the President of Vital Living. Mr. Hannah, a citizen of the United States of America, is a Non-executive Director of Vital Living. The business address for Mr.

CUSIP NO. 92846Y100

PAGE 6 OF 9 PAGES

Edson, Mr. Benson and Mr. Hannah is 5080 North 40th Street, Suite 105, Phoenix, Arizona 85018.

Mr. Morris, a citizen of the United Kingdom, is the sole officer and director of ENI and president of Fifth Avenue Capital. His business address is 32 Lancaster Mews, London, W2 3QE, England. Fifth Avenue Capital, a British Virgin Islands corporation, is a company that invests in international business opportunities, with its principal offices located at Suite 1601-1603, Kinwick Centre, 32 Hollywood Road, Central Hong Kong. None of the persons listed in Item 5(a), to SkyePharma's knowledge, has during the last five years been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(c) There have been no transactions by SkyePharma nor, to SkyePharma's knowledge, by any of the other persons listed in Item 5(a) in the class of securities reported on in this Statement that were effected during the past sixty days other than (i) the grant by the Issuer to Mr. Edson of 1,300,000 shares of Common Stock and (ii) the amendment of the warrant agreement with Mr. Benson eliminating the full ratchet anti-dilution protection provision therein and settling the total number of shares of Common Stock subject to or issuable under any warrant agreements or other derivative securities to Mr. Benson to be 6,310,000 after the Effective Time, and (iii) otherwise, as set forth in this Statement.

(d) No person other than SkyePharma has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, its Common Stock or Preferred Stock.

ITEM 6 CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

SkyePharma and the Issuer entered into the Subscription Agreement pursuant to which SkyePharma purchased 1,000,000 shares of Preferred Stock convertible into Common Stock subject to the conditions set forth in Sections 5 and 6 thereof.

Edgar Filing: VITAL LIVING INC - Form SC 13D

Pursuant to the terms of the Commitment Letter between SkyePharma and the Issuer, dated as of August 20, 2003, executed pursuant to Section 5 of the Merger Agreement, SkyePharma has committed to invest 1,000,000 U.S. dollars in the event that the Issuer raises an additional 3,000,000 U.S. dollars in an equity offering completed within 90 days of the Closing of the Merger, subject to the terms of such Commitment Letter. This obligation, if consummated, would be expected to result in an additional holding of 1,000,000 preferred convertible securities (the "Additional Preferred Stock") convertible into approximately 1,000,000 shares of Common Stock or more, depending on the price of such issuance and the conversion price and other terms of the Additional Preferred Stock.

SkyePharma, the Issuer, Mr. Edson, Mr. Benson, Mr. Morris, Mr. Hannah and Fifth Avenue Capital have entered into a Stockholders' Agreement, dated as of August 20, 2003, which contains the terms that are summarized below:

Board of Directors

The Board of the Issuer will consist of nine members. So long as the Founders Group beneficially owns in aggregate at least 65% of the shares of Common Stock (including any share of Capital Stock of the Issuer Convertible into Common Stock) owned by it at the date of the

CUSIP NO. 92846Y100

PAGE 7 OF 9 PAGES

execution of the Stockholders' Agreement, it is entitled to nominate four directors. So long as the Morris Group beneficially owns in aggregate at least 65% of the shares of Common Stock (including any share of Capital Stock of the Issuer Convertible into Common Stock) owned by it at the date of the execution of the Stockholders' Agreement, it is entitled to nominate one director. So long as SkyePharma beneficially owns in aggregate at least 65% of the shares of Common Stock (including any share of Capital Stock of the Issuer Convertible into Common Stock) owned by it at the date of execution of the Stockholders' Agreement, it is entitled to nominate one director. Each of the Founders Group, the Morris Group and SkyePharma covenants that it will vote in favor of the other Stockholders' nominee or nominees. Each Stockholder furthermore agrees that it will not take any action, or cause the Issuer to take any action, to remove, with or without cause, a director nominated by another Stockholder.

Vacancies

At any time a vacancy is created or exists on the Board of the Issuer, the remaining directors (if any) representing the Stockholder whose Board seat is vacant shall have the right to designate the person to fill the vacancy. If no directors representing the Stockholder remain, the Stockholder shall have the right to designate the person to fill the vacancy. All other Stockholders are obligated to vote in favor of such nominee.

To SkyePharma's knowledge and belief, none of its executive officers or directors named in Annex A hereto, have entered into any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to any securities of the Issuer.

SkyePharma and the Issuer entered into a Registration Rights Agreement, dated as of August 20, 2003 (the "Registration Rights Agreement"), pursuant to which the Issuer is obligated to prepare and file with the Securities and

Edgar Filing: VITAL LIVING INC - Form SC 13D

Exchange Commission (the "SEC") as soon as reasonably practicable after March 31, 2004 a registration statement (the "Registration Statement") to permit the offering and sale pursuant to Rule 415 of SkyePharma's restricted shares, as defined in the Registration Rights Agreement (the "Restricted Shares"). If the Issuer fails to file and maintain the Registration Statement, SkyePharma is entitled to demand the filing of the Registration Statement within 20 days of the notice of demand and the Issuer is obligated to comply. The Registration Rights Agreement also provides for "piggyback" registration, whereby if the Issuer intends to register shares under the Securities Act of 1933 (the "Securities Act") other than on Form S-4 or S-8, it must provide SkyePharma with notice of the proposed registration, and SkyePharma can require the Issuer to include its Restricted Shares in the registration statement and offering on the same terms and conditions as the shares otherwise being sold in such registration. The Registration Rights Agreement also contains covenants whereby the Issuer must use its best efforts to ensure that SkyePharma has a readily realizable market for its shares of Common Stock, including using its reasonable best efforts to obtain a listing for the Common Stock prior to December 31, 2003 and, in the event the Common Stock is not listed by such date, using its best efforts to procure purchasers for SkyePharma's Restricted Shares.

ITEM 7. MATERIALS TO BE FILED AS EXHIBITS.

- Exhibit 1. Registration Rights Agreement between Vital Living, Inc. and SkyePharma PLC, dated as of August 20, 2003.
- Exhibit 2. Subscription Agreement between Vital Living, Inc. and SkyePharma PLC, dated as of August 20, 2003.
- Exhibit 3. Commitment Letter of SkyePharma PLC, dated as of August 20, 2003.

CUSIP NO. 92846Y100

PAGE 8 OF 9 PAGES

- Exhibit 4. Stockholders' Agreement, between SkyePharma PLC, Vital Living Inc., Bradley Edson, Stuart Benson, Donald Hannah, Stephen Morris and Fifth Avenue Capital Inc., dated as of August 20, 2003.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 29, 2003

SkyePharma PLC

By: /s/Donald Nicholson

Name: Donald Nicholson
Title: Finance Director

Edgar Filing: VITAL LIVING INC - Form SC 13D

 CUSIP NO. 92846Y100

PAGE 9 OF 9 PAGES

ANNEX A

The name, position, present principal occupation and address thereof and citizenship of each director and executive officer of SkyePharma is set forth below.

The business address for SkyePharma and each of the executive officers and directors listed below is SkyePharma PLC, 105 Piccadilly, London, England W1J 7NJ.

NAME	POSITION	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND ADDRESS
Ian Gowrie-Smith	Executive Chairman	
Michael Ashton	Chief Executive Officer	
Donald Nicholson	Finance Director and Executive Director	
Air Chief Marshal Sir Michael Beavis	Senior Independent Non-executive Director	Retired
Dr. David Ebsworth	Non-executive Director	Non-executive Director of Clal Biotechnology Industries and CuraGen Corporation
R. Stephen Harris	Non-executive Director	Non-executive Chairman of Proteome Sciences plc and Non-executive Director of Advanced Medical Solutions Group plc, Microscience Ltd, Prophilian plc, Sinclair Pharma Limited and GeneMedix plc
Dr. Keith Mansford	Non-executive Director	External Director of Sepracor Inc., Chairman of Mansford Associates, Non-executive Chairman of Conve Limited and Professor of Biochemistry at the University of Buckingham.
Dr. Argeris (Jerry) Karabelas	Non-executive Director	Partner at Care Capital LLC, External Director of Human Genome Sciences, Fox Chase Cancer Center, The University of the Sciences in Philadelphia, Member of the Scientific Advisory Committee of the Massachusetts General Hospital, Boston, Director of NitroMed Inc., Halsey Pharmaceuticals, Anadys, Renolvo and a Member of the Scientific Advisory Board of Epigenesis.

Edgar Filing: VITAL LIVING INC - Form SC 13D

Torao Yamamoto

Non-executive
Director

Senior Managing Director of the Pharmaceutical Division of Kowa Company Limited in Japan, Member of the Board of Directors of Kowa Company Limited, Kowa Pharmaceutical Europe, Ltd., and Kowa Research Europe, Ltd.